A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: SAGE-217
DRUG: Levodopa
DRUG: Antiparkinsonian Agent(s)

Sponsor

Biogen